Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease

Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA® for an indication of Crohn’s disease

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President and Representative Director: Masayuki Mitsuka, hereinafter, Mitsubishi Tanabe Pharma) recently signed a co-promotion agreement with Janssen Pharmaceutical K.K. (Headquarters: Chiyoda-ku, Tokyo; President: Chris Hourigan, hereinafter, Janssen) for STELARA® (ustekinumab) for an indication of Crohn’s disease. Janssen has filed an application in Japan for this indication for STELARA®, a monoclonal antibody that binds to the p40 subunit of human anti-interleukin (IL)-12 and IL-23.

Under the terms of this agreement, after Janssen obtains approval for this indication, Janssen will conduct to distribution while the two companies will jointly promote STELARA®.

Since May 2002, Mitsubishi Tanabe Pharma has distributed intravenous injection formulation of REMICADE® as a treatment agent for Crohn’s disease. Moving forward, Mitsubishi Tanabe Pharma will distribute REMICADE® and promote STELARA®, which has a different mechanism of action. In this way, Mitsubishi Tanabe Pharma plans to provide a new choice in the treatment of Crohn’s disease.

In addition, in September 2011 Mitsubishi Tanabe Pharma and Janssen began to facilitate co-operation of SIMPONI®, an RA treatment agent in a subcutaneous injection formulation. From April 2016, however, Mitsubishi Tanabe Pharma has distributed SIMPONI® while the two companies have jointly promoted. In Japan an application for an additional indication of ulcerative colitis has been filed for SIMPONI®, and plans commercialization to be handled under the same framework after approval is received.

Going forward, in the field of inflammatory bowel disease (Crohn’s disease, ulcerative colitis), Mitsubishi Tanabe Pharma will offer REMICADE® and STELARA® for the indication of Crohn’s disease and REMICADE® and SIMPONI® for the indication of ulcerative colitis. In this way, Mitsubishi Tanabe Pharma will strive to strategically reinforce its foundation in the field of inflammatory bowel disease and contribute to improvements in patients’ quality of life and to their medical treatment.

〈〈For Details, Contact the Following Section〉〉

Corporate Communications Department
Tel +81-6-6205-5211